Literature DB >> 32959232

Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer.

Yueming Zhang1, Yaolin Xu1, Dansong Wang1, Tiantao Kuang1, Wenchuan Wu1, Xuefeng Xu1, Dayong Jin1, Wenhui Lou2.   

Abstract

BACKGROUND: Inflammatory factors and fasting blood glucose were verified to be associated with the prognosis of pancreatic ductal adenocarcinoma. The goal of this study is to confirm the prognostic role of preoperative blood glucose to lymphocyte ratio for patients with resected pancreatic ductal adenocarcinoma.
METHODS: A total of 259 pancreatic ductal adenocarcinoma patients were enrolled and randomly divided into training cohort and validation cohort. The training cohort was used to generate an optimal cutoff value and the validation cohort was used to further validate the model.
RESULTS: A total of 259 patients were incorporated in this study and randomly divided into the training cohort (n = 130, 1/2 of 259) and the validation cohort (129, 1/2 of 259). The optimal cutoff value of glucose to lymphocyte ratio was calculated to be 3.47 for overall survival. Cox regression analysis found that preoperative blood glucose to lymphocyte ratio was independent risk factor (p = 0.040) for overall survival. Prognostic values of glucose to lymphocyte ratio on overall survival were observed in younger male patients with pancreatic body and tail cancer, American Joint Committee on Cancer 8th N1 stage, without microvascular and peripancreatic fat invasion, and Carbohydrate antigen 19-9 higher than 200 U/ml. A prognostic prediction model of overall survival was designed and presented in nomogram.
CONCLUSION: Preoperative blood glucose to lymphocyte ratio is an independent biomarker to predict the overall survival for pancreatic ductal adenocarcinoma patients who underwent curative resection.

Entities:  

Keywords:  Glucose to lymphocyte ratio; Overall survival; Pancreatic ductal adenocarcinoma; Prognosis

Year:  2020        PMID: 32959232     DOI: 10.1007/s10147-020-01782-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  28 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.

Authors:  Ulrich Halm
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

Review 3.  Pancreatic adenocarcinoma.

Authors:  David P Ryan; Theodore S Hong; Nabeel Bardeesy
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

4.  Colorectal carcinoma antigens detected by hybridoma antibodies.

Authors:  H Koprowski; Z Steplewski; K Mitchell; M Herlyn; D Herlyn; P Fuhrer
Journal:  Somatic Cell Genet       Date:  1979-11

5.  Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.

Authors:  Christopher L Hallemeier; Maikel Botros; Michele M Corsini; Michael G Haddock; Leonard L Gunderson; Robert C Miller
Journal:  Am J Clin Oncol       Date:  2011-12       Impact factor: 2.339

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 7.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

8.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

Review 9.  Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future.

Authors:  Aline Barhli; Jérôme Cros; Laurent Bartholin; Cindy Neuzillet
Journal:  Dig Liver Dis       Date:  2018-08-20       Impact factor: 4.088

10.  A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma.

Authors:  Shinichi Ikuta; Takashi Sonoda; Tsukasa Aihara; Naoki Yamanaka
Journal:  Ann Transl Med       Date:  2019-09
View more
  5 in total

1.  Frailty is associated with poor prognosis after resection for pancreatic cancer.

Authors:  Kosuke Mima; Hiromitsu Hayashi; Shigeki Nakagawa; Takashi Matsumoto; Shotaro Kinoshita; Kazuki Matsumura; Fumimasa Kitamura; Norio Uemura; Yosuke Nakao; Rumi Itoyama; Takayoshi Kaida; Katsunori Imai; Yo-Ichi Yamashita; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2021-07-07       Impact factor: 3.402

2.  Prognostic Value of Glucose-to-Lymphocyte Ratio in Critically Ill Patients with Acute Pancreatitis.

Authors:  Yongjun Chen; Shangjun Tang; Yumei Wang
Journal:  Int J Gen Med       Date:  2021-09-08

3.  Preoperative Glucose-to-Lymphocyte Ratio is an Independent Predictor for Acute Kidney Injury After Cardiac Surgery in Patients in Intensive Care Unit.

Authors:  Lu Li; Gaorui Zou; Jie Liu
Journal:  Int J Gen Med       Date:  2021-10-08

4.  Association between glucose-to-lymphocyte ratio and in-hospital mortality in intensive care patients with sepsis: A retrospective observational study based on Medical Information Mart for Intensive Care IV.

Authors:  Shaoyan Cai; Qinjia Wang; Chuzhou Ma; Junheng Chen; Yang Wei; Lei Zhang; Zengqiang Fang; Liangjie Zheng; Chunming Guo
Journal:  Front Med (Lausanne)       Date:  2022-08-24

5.  Prognostic value of glucose to lymphocyte ratio for patients with renal cell carcinoma undergoing laparoscopic nephrectomy: A multi-institutional, propensity score matching cohort study.

Authors:  Jinliang Ni; Ziye Li; Wei Song; Houliang Zhang; Yidi Wang; Yifan Zhang; Haipeng Zhang; Guangcan Yang; Jun Xie; Keyi Wang; Bo Peng; Weipu Mao
Journal:  Front Surg       Date:  2022-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.